Skip to content
Homepage
Author:
Arvinas Inc.
Posted Date:
June 4, 2026
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
Arvinas Inc.
June 4, 2026
Arvinas to Present at Jefferies Global Healthcare Conference
Arvinas Inc.
May 29, 2026
Arvinas Employees Give Back During Company-wide Impact Day
Arvinas Inc.
May 18, 2026
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
Arvinas Inc.
May 12, 2026
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
Arvinas Inc.
May 12, 2026
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
Arvinas Inc.
May 12, 2026
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
Arvinas Inc.
May 5, 2026
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
Arvinas Inc.
May 3, 2026
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
Arvinas Inc.
March 18, 2026
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Arvinas Inc.
March 11, 2026
1
2
Next
